Katharine Hsu
Katharine Chia-Rae Hsu | |
|---|---|
| Alma mater | Stanford University (BS, MS) Cornell University (PhD, MD) |
| Known for | Director of Tri-Institutional MD–PhD Program since 2021 |
| Scientific career | |
| Fields | Hematology, oncology |
| Institutions |
|
| Thesis | Mechanisms of TNF receptor action: Studies using chimeric receptor mutants (1993) |
| Doctoral advisor | Moses Chao |
Katharine Chia-Rae Hsu[1] is an American physician-scientist with a field of research in human natural killer cells. A professor of medicine at Weill Cornell Medicine, she has served as the director of the Tri-Institutional MD–PhD Program since April 2021.
Early life and education
[edit]Hsu lived in Tuxedo Park, New York for fifteen years.[2] Hsu received a Bachelor of Science and a Master of Science from Stanford University in 1987. She received a Doctor of Philosophy in cell biology in 1993 and a Doctor of Medicine in 1994, both from Cornell University.[3][4][5]
During her doctoral studies at Cornell University, she studied at the laboratory of Moses Chao,[5] who was her doctoral advisor.[6][failed verification] Her doctoral dissertation was titled, Mechanisms of TNF receptor action: Studies using chimeric receptor mutants.[6]
Hsu completed an internship and residency in internal medicine at Brigham and Women's Hospital in Boston in 1997.[5] She completed a postdoctoral fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center in New York City in 2002.[5][7]
Career
[edit]Hsu joined the faculty of Cornell Medical College. She worked as an instructor of medicine from 2003 to 2008, as an assistant professor of medicine from 2008 to 2011 and as an associate professor of medicine from 2011 to 2016.[8] She was inducted into the American Society for Clinical Investigation in 2012.[5] She became a professor of medicine in 2017.[8] Her field of research is natural killer cells in humans and their role in killing cancer cells and cells with viruses.[5]
In April 2021, Hsu was named the director of the Tri-Institutional MD–PhD Program, succeeding Olaf Sparre Andersen.[5]
References
[edit]- ^ "Mechanisms of TNF receptor action: Studies using chimeric receptor mutants - ProQuest". www.proquest.com. Retrieved 2024-10-30.
- ^ "Tuxedo Farms Submitted Questions and Comments" (PDF). The Town of Tuxedo. p. 7. Archived (PDF) from the original on 2023-06-15. Retrieved 2024-10-30.
- ^ "Hsu, Katharine". vivo.weill.cornell.edu. Retrieved 2024-10-30.
- ^ "Katharine C. Hsu, MD, PhD - MSK Bone Marrow Transplant Specialist". www.mskcc.org. Retrieved 2024-10-30.
- ^ a b c d e f g "Dr. Katharine Hsu Named Director of Tri-Institutional M.D.-Ph.D. Program". WCM Newsroom. April 9, 2021. Retrieved 2024-01-20.
- ^ a b Hsu, Katherine C. (1993). Mechanisms of TNF Receptor Action: Studies Using Chimeric Receptor Mutants (Ph.D. thesis). Cornell University. OCLC 39556864.
- ^ "Dr. Katharine Hsu, MD, PhD, Oncology | New York, NY | WebMD". doctor.webmd.com. Retrieved 2024-10-30.
- ^ a b "Hsu, Katharine". vivo.weill.cornell.edu. Retrieved 2024-01-20.
